NCT07413939 2026-03-10
BREnnA
Hoffmann-La Roche
Phase 2/3 Not yet recruiting
Clinical Trials
29 trialsNCT07377643 2026-02-25
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3 Recruiting
NCT06830889 2026-01-22
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03975647 2025-12-10
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT05253911 2025-12-04
TRACE
iOMEDICO AG
Completed
NCT06891833 2025-10-02
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Recruiting
NCT07043725 2025-09-23
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT06316531 2025-08-19
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT06445400 2025-08-03
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05514717 2025-07-11
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Mersana Therapeutics
Phase 1 Recruiting
NCT06833268 2025-07-08
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
Daiichi Sankyo
Completed
NCT05511844 2025-07-04
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Orum Therapeutics USA, Inc.
Phase 1 Terminated
NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
NCT06968585 2025-05-13
A166
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 3 Active not recruiting
NCT03133988 2025-02-14
Margetuximab Expanded Access Program
TerSera Therapeutics LLC
Approved for marketing
NCT05149014 2024-09-26
Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer
Daiichi Sankyo France
Completed
NCT03330561 2024-04-22
PRS-343 in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
NCT03650348 2024-04-22
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
NCT05458401 2024-03-15
EUROPA T-DXd
Daiichi Sankyo
Completed
NCT06107790 2023-10-30
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 3 Completed
NCT03953833 2023-09-14
B003-101
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1 Completed
NCT05769751 2023-08-16
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer
Daiichi Sankyo
Completed
NCT05985187 2023-08-14
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT04395508 2022-07-05
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Genentech, Inc.
Approved for marketing
NCT05334810 2022-04-19
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT03281824 2022-01-18
Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients
Alteogen, Inc.
Phase 1 Completed
NCT04170595 2021-03-03
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Genor Biopharma Co., Ltd.
Phase 1/2 Unknown